Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.
Bokhari
Sw
S
Das-Gupta
E
E
Russell
Nh
N
Byrne
J
J
D000074323:Alemtuzumab; D000754:Anemia, Refractory, with Excess of Blasts / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy; D000069283:Rituximab; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D000069283:Rituximab